FAP and colorectal cancer: However, no FAP-targeted therapy has demonstrated efficacy in colorectal cancer patients, as both sibrotuzumab (a FAP-targeted mAb) and talabostat (a small molecule FAP-inhibitor) were incapable of successfully passing phase II trials43,44.